TABLE 2.
Clinicopathological characteristics and preoperative laboratory parameters of patients with rectal cancer liver-only metastases.
| Parameters | N (%) | Median (range) | Cut-off value RFS/OS | |
|---|---|---|---|---|
| Age (yrs) | 62 (31–81) | 68/64 | ||
| <68 | 68 (66) | |||
| ≥68 | 35 (34) | |||
| <64 | 58 (56) | |||
| ≥64 | 45 (44) | |||
| Gender | ||||
| male | 69 (67) | |||
| female | 34 (33) | |||
| Type of surgery used for metastasectomy | ||||
| laparoscopy | 19 (18) | |||
| open | 84 (82) | |||
| Resection margin | ||||
| R0 | 65 (63) | |||
| R1 | 38 (37) | |||
| Synchronicity of primary surgery and metastasectomy | ||||
| synchronous | 10 (10) | |||
| metachronous | 93 (90) | |||
| “liver first” | 10 (11) | |||
| Preoperative (metastasectomy) chemotherapy ± targeted therapy | ||||
| none | 37 (36) | |||
| yes | 66 (64) | |||
| targeted | 41 (62) | |||
| Postoperative (metastasectomy) chemotherapy ± targeted therapy | ||||
| none | 29 (28) | |||
| yes | 74 (72) | |||
| targeted | 23 (31) | |||
| Pre- or postoperative chemotherapy ± targeted therapy | ||||
| none | 13 (13) | |||
| yes | 90 (87) | |||
| targeted | 49 (54) | |||
| WBC (G/l) | 5.9 (3.4–18.6) | 7.3/4.2 | ||
| <7.3 | 79 (77) | |||
| ≥7.3 | 24 (23) | |||
| <4.2 | 14 (14) | |||
| ≥4.2 | 89 (86) | |||
| neutrophil (G/l) | 3.8 (2–13.5) | 5.5/3.5 | ||
| <5.5 | 85 (83) | |||
| ≥5.5 | 18 (17) | |||
| <3.5 | 37 (36) | |||
| ≥3.5 | 66 (64) | |||
| lymphocyte (G/l) | 1.4 (0.4–3.6) | 0.97/1.7 | ||
| <0.97 | 32 (31) | |||
| ≥0.97 | 71 (69) | |||
| <1.7 | 77 (75) | |||
| ≥1.7 | 26 (25) | |||
| platelet (G/l) | 210 (111–396) | 161/314 | ||
| <161 | 18 (17) | |||
| ≥161 | 85 (83) | |||
| <314 | 90 (87) | |||
| ≥314 | 13 (13) | |||
| NLR | 2.9 (0.9–11.3) | 2.42/2.56 | ||
| <2.42 | 31 (30) | |||
| ≥2.42 | 72 (70) | |||
| <2.56 | 39 (38) | |||
| >2.56 | 64 (62) | |||
| SII (G/l) | 616 (189–3,500) | 792/742 | ||
| <792 | 65 (63) | |||
| ≥792 | 38 (37) | |||
| <742 | 63 (61) | |||
| ≥742 | 40 (39) | |||
| GOT (U/l) | 23 (9–72) | 25/20 | ||
| <25 | 50 (58) | |||
| ≥25 | 36 (42) | |||
| <20 | 20 (23) | |||
| ≥20 | 66 (77) | |||
| NA | 17 | |||
| GPT (U/l) | 19 (5–77) | 22/13 | ||
| <22 | 52 (60) | |||
| ≥22 | 34 (40) | |||
| <13 | 13 (15) | |||
| ≥13 | 73 (85) | |||
| NA | 17 | |||
| Site of progression | ||||
| liver | 43 (42) | |||
| lung | 21 (20) | |||
| liver+lung | 8 (8) | |||
| other | 13 (13) | |||
| Extent of progression | ||||
| single | 69 (67) | |||
| multiple | 16 (16) | |||
| none | 18 (17) | |||
GOT, aspartate aminotransferase; GPT, alanine aminotransferase; NA, not available; NLR, neutrophil-to lymphocyte ratio; OS, overall survival; RFS, relapse-free survival; SII, systemic immune-inflammation index; WBC, white blood cells.